ReviewDrug safety2008
Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.
Review in Drug safety, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 148 citations in OpenAlex.
- Patterns of sexual dysfunction among breast cancer survivors five years after diagnosis: a latent class analysis of the French VICAN5 study.Journal of cancer survivorship : research and practice · 2026Article
- Article
- The ADAPT-HEAT Study: A Multi-Method Approach to Develop Recommendations for Drug Safety During Hot Weather (The CALOR List)-Study Protocol.Methods and protocols · 2026Article
- Oxybutynin treatment for episodic hyperhidrosis in Parkinson disease.Journal of Parkinson's disease · 2026Article
- Identification of potentially heat-vulnerability increasing drugs - a narrative review.European journal of clinical pharmacology · 2026Review
- Fever and syndrome of inappropriate antidiuretic hormone secretion in a patient with multiple system atrophy after treatment with duloxetine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Oritavancin safety: a real-world pharmacovigilance study of the FAERS database.Frontiers in cellular and infection microbiology · 2026Article
- Medications, epilepsy and climate change: Added layers of complexity.British journal of clinical pharmacology · 2025Review
- Effects of environmental temperature on mortality in cancer patients in palliative care.BMC palliative care · 2025Article
- Overexposed and Understudied: Environmental Risks Among Older Adults Experiencing Homelessness in Phoenix, Arizona.GeoHealth · 2025Article
- Article
- Assessing the impact of heatwaves on emergency visits for major depression and suicidal ideation in youth with attention-deficit/hyperactivity disorder.PLOS mental health · 2025Article
- Primary hyperhidrosis: an updated review.Drugs in context · 2025Review
- A Review of the Etiologies and Key Clinical Features of Secondary Hyperhidrosis.American journal of clinical dermatology · 2025Review
- From Evidence to Practice: A Comprehensive Analysis of Side Effects in Synthetic Anti-Depressant Therapy.Current drug safety · 2025Review
- Acute Hyperhidrosis: A Clue to Underlying Autonomic Dysfunction and a Rare Neurological Disorder.Cureus · 2024Article
- Climate change's implications for practice: Pharmacologic considerations of heat-related illness.The Nurse practitioner · 2024Article
- The Importance of Maintaining and Improving a Healthy Gut Microbiota in Athletes as a Preventive Strategy to Improve Heat Tolerance and Acclimatization.Microorganisms · 2024Review
- Experimental research in environmentally induced hyperthermic older persons: A systematic quantitative literature review mapping the available evidence.Temperature (Austin, Tex.) · 2024Article
- Indoor overheating: A review of vulnerabilities, causes, and strategies to prevent adverse human health outcomes during extreme heat events.Temperature (Austin, Tex.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human sweating response is subject to the influence of diverse classes of drugs. Some act centrally at the hypothalamus or at spinal thermoregulatory centres, while others act at sympathetic ganglia or at the eccrine-neuroeffector junction. Pharmacological disturbances of sweating have broad clinical implications. Drugs that induce hyperhidrosis, or sweating in excess of that needed to maintain thermoregulation, can cause patient discomfort and embarrassment, and include cholinesterase inhibitors, selective serotonin reuptake inhibitors, opioids and tricyclic antidepressants. Drugs that induce hypohidrosis, or deficient sweating, can increase the risk of heat exhaustion or heat stroke and include antimuscarinic anticholinergic agents, carbonic anhydrase inhibitors and tricyclic antidepressants. As acetylcholine is the principal neuroeccrine mediator, anhidrosis is one of the clinical hallmarks by which acute anticholinergic toxicity may be recognized. The symptom of dry mouth often accompanies the less apparent symptom of hypohidrosis because the muscarinic M(3) acetylcholine receptor type predominates at both sweat and salivary glands. Management options include dose reduction, drug substitution or discontinuation. When compelling medical indications require continuation of a drug causing hyperhidrosis, the addition of a pharmacological agent to suppress sweating can help to reduce symptoms. When hypohidrotic drugs must be continued, deficient sweating can be managed by avoiding situations of heat stress and cooling the skin with externally applied water. The availability of clinical tests for the assessment of sudomotor dysfunction in neurological disease has enhanced recognition of the complex effects of drugs on sweating. Advances in the understanding of drug-induced anhidrosis have also enlarged the therapeutic repertoire of effective treatments for hyperhidrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.